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Abstract
Objectives
To assess the non-specific effect of Bacillus Calmette-Guérin (BCG) vaccination at birth on
psychomotor development.
Design
This is a pre-specified secondary outcome from a randomised, clinical trial.
Setting
Maternity units and paediatric wards at three university hospitals in Denmark.
Participants
Children born at gestational age (GA) 32 weeks and above. All women planning to give birth
at the three sites were invited during the recruitment period. Out of 4262 randomised chil-
dren, 144 were premature (GA < 37 weeks). There were 2129 children (71 premature) ran-
domised to BCG and 2133 randomised (73 premature) to the control group.
Interventions
BCG vaccination 0.05 ml was given intradermally in the upper left arm at the hospital within
seven days of birth. Children in the control group did not receive any intervention. Parents
were not blinded to allocation.
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Main outcomemeasures
Psychomotor development measured using Ages and Stages Questionnaire (ASQ) com-
pleted by the parents at 12 months. Additionally, parents of premature children (gestational
age < 37 weeks) completed an ASQ at 6 and 22 months. Developmental assessment was
available for 3453/4262 (81%).
Results
The mean difference in ASQ score at 12 months adjusted for age and prematurity was -0.7
points (BCG vs. control, 95% confidence interval; -3.7 to 2.4), p = 0.67, corresponding to an
effect size of Cohen’s d = -0.015 (-0.082 to 0.052). The mean difference in ASQ score for
premature children at 22 months was -7.8 points (-20.6 to 5.0, p = 0.23), d = -0.23 (-0.62 to
0.15).
Conclusions
A negative non-specific effect of BCG vaccination at birth on psychomotor development
was excluded in term children.
Trial Registration
ClinicalTrials.gov NCT01694108
Introduction
The Bacillus Calmette-Guérin vaccine (BCG) against tuberculosis is one of the most commonly
used vaccines globally. Approximately 100 million children receive it every year. The vaccine
provides some protection against both infection withM. tuberculosis and progression to tuber-
culous disease in children[1]. WHO recommends BCG at birth in countries with a high preva-
lence of tuberculosis[2]. A randomised trial[3] and several observational studies[4–7] have
shown that BCG has non-specific beneficial effects resulting in lower mortality and morbidity
from infections[8] among BCG vaccinated children in low-income countries. The reduction in
mortality and morbidity from infections was larger than what could be explained by prevention
of tuberculosis, i.e. a non-specific effect. Also, BCG has been associated with a decrease in
atopic disease[9]. Child mortality in Denmark is low but infectious and allergic diseases are
common[10]. On that basis, a large randomised trial—The Danish Calmette Study—was con-
ducted to examine if BCG given at birth would reduce childhood morbidity in a high-income
country[11].
To our knowledge, the possible non-specific effects of BCG on child psychomotor develop-
ment have not previously been studied. BCG vaccination induces inflammatory Th1-responses
and Th2-responses to unrelated pathogens in vaccinated children[12,13]. BCG also causes
localised inflammation at the site of injection for several months[14]. Early life exposure to
low-grade inflammation has been linked to development of neuropsychiatric disorders such as
cognitive disorders, cerebral palsy, and autism spectrum disorders[15,16]. It has also been asso-
ciated with increased susceptibility to damage following a hypoxic-ischaemic insult in animal
models[17] and with changes in brain maturation in premature sheep[18]. For this reason we
wanted to investigate the BCG vaccine’s effect on the neuro-development—particularly
BCG and Child Psychomotor Development
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relevant for the use of BCG to prevent non-critical illness, and perhaps even more so for pre-
mature children who are thought to be more susceptible to inflammatory insults.
Therefore, a secondary outcome of The Danish Calmette Study[11] was to address the ques-
tion whether BCG at birth could have a negative effect on child development.
Methods
This study reports on a secondary outcome of The Danish Calmette Study, described in detail
elsewhere[11]. Initially we had planned to study the development of premature children only,
but as we developed the web-platform for the parental report of child psychomotor develop-
ment for the premature children at six months, we realised that we would be able to assess the
entire cohort using the same approach and we sought and received ethical clearance to do that
in time for a 12 months report.
The study was approved by the Committees on Biomedical Research Ethics (J.no. H-3-
2010-087), the Danish Data Protection Board (J.no. 2009-41-4141), and the Danish Medicines
Agency (J.no. 2612–4356. EudraCT 2010-021979-85. Protocol 2009–323) and registered at
www.clinicaltrials.gov (NCT01694108). The trial was supervised by the Good Clinical Practice
Units of the Capital Region and the Region of Southern Denmark. The study was monitored
by an independent data and safety monitoring board with three members. All parents gave
written informed consent.
Trial methodology in brief
The trial took place at maternity units and paediatric wards at three university hospitals in
Denmark. Within seven days of birth, study staff randomised children to receive BCG (Danish
SSI strain 1331) in the standard dose of 0.05 mL intra-dermally on the left shoulder or to a no-
intervention control group. Parents were not blinded to allocation since the local inflammatory
reaction after BCG vaccination could not be mimicked. Randomisation was stratified by pre-
maturity (gestational age [GA]< 37 weeks or 37 weeks) and children were allocated 1:1 in
permuting blocks of 2-4-6 using an online system. Exclusion criteria were GA< 32 weeks,
birth weight< 1000 g, child critically ill, known immune-deficiency, no Danish-speaking par-
ent and maternal use of immune modulating drugs during pregnancy. Follow-up consisted of
telephone interviews and clinical examination at 3 and 13 months as well as hospital admission
diagnoses obtained from national registries at 15 months.
Follow-up for this study
The Ages and Stages Questionnaire (ASQ) is a series of validated parent-reported, age-related
questionnaires ranging from 2 to 60 months, designed to identify children with developmental
delay. Each questionnaire contains 30 items on every-day child activities within five sub-
domains (communication, fine motor development, gross motor development, problem solv-
ing, and personal and social development)[19]. Each item can be checked “yes”, “sometimes”,
or “not yet” by the parents. An item is scored 10 for “yes”, 5 for “sometimes”, and 0 for “not
yet” and a score for each sub-domain (0 to 60) and a total ASQ score (0 to 300) is calculated if
all sub-domains are completed. ASQ is designed to identify children with developmental delay,
i.e. those with scores on the left tail of the distribution. Children who score below– 1.5 SD are
considered at risk of developmental delay. The distribution of the total ASQ score is truncated
to the right when applied to the intended age-group. We wanted to obtain the highest power to
detect a difference in mean ASQ score and therefore aimed at a non-truncated distribution of
ASQ scores. To obtain this, we used the ASQ intended for children aged 8 months to our pre-
mature population at 6 months, the ASQ for 14 months old children to our entire cohort at age
BCG and Child Psychomotor Development
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12 months, and the ASQ for 24 months old children for our premature population at 22
months. When using an ASQ for a non-intended age group, it is not possible to determine an
optimal ASQ score a priori.
ASQ has not been published in Danish. We obtained permission from the publisher to use
a version (ASQ 2nd edition) translated for previous research use[20] and adapted it for online
use.
We distributed the online ASQ to the parents on the child’s first birthday using an automat-
ically generated email containing a link. We reminded the parents who had not filled in the
ASQ at the 13 month telephone and clinical follow-up. Parents of premature children also
received an ASQ when the child was 6 and 22 months old. Follow-up took place from April 8th
2013 to August 21st 2015.
Outcomes
The primary outcome of this study was ASQ score at one year for the entire cohort using com-
plete questionnaires. Sub-group analyses of premature vs. children born to term and boys vs.
girls at one year were planned. Secondary outcomes were ASQ score at 6, 12, and 22 months in
premature children and ASQ sub-domain scores in the entire cohort at 12 months using com-
plete questionnaires. All analyses were planned prior to un-blinding the data, except an explor-
atory analysis of the average effect of BCG on premature children at 6, 12, and 22 months
which was decided post hoc.
Sample size, data management and statistics
The original sample size of The Danish Calmette Study (4300 children) was determined to be
able to detect a 20% reduction in number of hospitalisations up to 15 months with a power of
90%[11]. With this sample size, a significance level of 0.05, and a mean ASQ score of 200 with
a standard deviation (SD) of 40, this study has a power of 98% to detect a 5 point difference
(effect size 0.13) in mean ASQ score at one year. We expected 5.5% of the cohort to be prema-
ture (GA< 37 weeks) yielding a power of 50% to detect a 10 point difference (effect size 0.25)
in premature children.
At each follow-up, we grouped parents into responders if the questionnaire was complete,
partial responders if the questionnaire was incomplete and non-responders if the questionnaire
was missing.
Continuous outcomes were analysed using multiple regression models adjusting for child
age at follow-up and for prematurity (binary variable, GA or< 37 weeks), and raw estimates
are presented as well as Cohen’s d effect size; calculated as the beta-coefficient divided by the
square root of the mean residual variance. The primary analysis was a regression model adjust-
ing for prematurity using complete cases only. Secondary outcomes are reported if all questions
within the ASQ sub-domain were answered. A primary outcome sensitivity analyses was con-
ducted adjusting for variables that could be associated with missing outcome; i.e. age at follow-
up, child sex, study site, gestational age in days, maternal year of birth, maternal education,
multiple birth, maternal smoking during pregnancy, older siblings. Due to a data management
system error premature children with gestational age of 32 weeks to 33 weeks and 3 days did
not receive the ASQ at 6 months. This mechanism of lost to follow-up was interpreted as miss-
ing at random since the probability of being missing was not associated with the outcome. To
explore this, we used general/multivariate normal linear models estimated by maximum likeli-
hood to examine the associations between BCG and ASQ score across time for premature chil-
dren taking into account correlation of measurements within children. The model includes a
follow-up variable and an interaction between BCG and follow-up allowing separate effects of
BCG and Child Psychomotor Development
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BCG to be estimated at 6, 12, and 22 months. Unstructured covariance matrices were used to
keep variances and correlations unconstrained. The model is often called Multivariate- or
Mixed Model Repeated Measures denoted MMRM.
Slight right-truncation was detected at 12 month follow-up (S1 Fig) but the residuals of the
regression were normally distributed, i.e. the assumptions of the primary regression analysis
were met. Non-normally distributed discrete data were analysed using Mann-Whitney U-test.
Categorical outcomes were analysed using χ2. The significance level was 0.05 and all tests were
two-tailed. All analyses reported are intention-to-treat analyses.
All analyses were performed using STATA 13.1 (StataCorp, Texas, USA). The statistical
code used is available in S1 Text.
Results
Between October 2012 and November 2013, a total of 16 521 pregnant women were invited.
We enrolled 4184 mothers and their 4262 newborn children were randomised (Fig 1). Baseline
characteristics were evenly distributed between allocation groups except non-Danish ethnicity
and paternal smoking during pregnancy, both of which were more frequent in the control
group (Stensballe, 2015). Baseline characteristics grouped by response to follow-up question-
naires are presented in Table 1.
There were 350/2129 (16.4%) partial responders and non-responders in the BCG group
vs. 459/2133 (21.5%) in the control group, p< 0.001. Among partial responders and non-
responders, there were significantly more women with basic schooling and non-theoretical
training (212/809 [26.2%] vs. 695/3453 [20.1%]; p< 0.001), and more families with siblings
(370/807 [two were unknown] [45.9%] vs. 1391/3453 [40.3%]; p = 0.004).
There were 46/144 (32.4%) premature partial responders and non-responders at 6 months,
29/144 (20.1%) at 12 months and 22/144 (15.3%) at 22 months.
The mean ASQ score among the 3453 children with complete questionnaires at 12 months
was 178.2 points (SD 52.4) in the BCG group vs. 179.9 points (SD 53.6) in the control group. A
total of 22 children scored the maximum score of 300.
Primary and secondary outcomes
The mean difference in ASQ score at 12 months adjusted for age and prematurity was -0.7
points (BCG vs. control, 95% confidence interval [95% CI]; -3.7 to 2.4, p = 0.67), corresponding
to an effect size of d = -0.015 (-0.082 to 0.052). There were no statistically significant differences
in any of the ASQ sub-domains (Table 2). At 22 months, the effect of BCG in premature chil-
dren was -7.8 points (-20.6 to 5.0), d = -0.23 (-0.62 to 0.15). The mean differences in premature
children at 6 months and 12 months were also negative but not statistically significant and
the effect of BCG was not statistically significantly different between premature and term chil-
dren at 12 months (Table 3). The results were essentially the same in per protocol analyses
(Table 4).
In premature children, the effect of BCG did not differ significantly at 6, 12, and 22 months,
p = 0.47. The mean effect of BCG was not significant when combining the three estimates;
BCG vs. control: -6.4 points (-15.6 to 2.8), p = 0.17. There is no consistent pattern in which
sub-domain scores are affected at 6, 12, and 22 months for premature children (Fig 2). Adjust-
ment for factors possibly related to non-response in the sensitivity analysis did not change the
estimates significantly (Table 5).
In the entire cohort at one year, the mean, age-adjusted BCG effect for boys was -3.2 points
(-7.4 to 0.9), d = -0.072 (-0.16 to 0.020) and 2.0 points (-2.4 to 6.4), d = 0.045 (-0.052 to 0.14)
BCG and Child Psychomotor Development
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for girls. The difference in effect between boys and girls was not significant (p = 0.087 for
interaction).
Discussion
In the present study, we report a pre-specified secondary analysis of a randomised, clinical
trial, investigating whether BCG vaccination at birth affects the psychomotor development of
children. We found no effect of BCG on the psychomotor development at 12 months of age.
The study has sufficient power to detect even a small difference in ASQ score among the
mature children and thus has a low risk of not detecting a clinically relevant effect. To measure
Fig 1. Participant flowchart.
doi:10.1371/journal.pone.0154541.g001
BCG and Child Psychomotor Development
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Table 1. Baseline characteristics by randomisation group and response to primary outcome follow-up questionnaire at 12 months.
N = 4262 Responders Partial responders and non-
responders
(n = 3453) (n = 809)
BCG
(n = 1779)
Control
(n = 1674)
BCG
(n = 350)
Control
(n = 459)
Maternal age, yrs Mean (SD) 31.6 (4.5) 31.6 (4.3) 31.1 (5.2) 31.1 (4.7)
Maternal education# N (%)
Basic schooling and non-theoretical education 367 (20.6%) 328 (19.6%) 98 (28.0%) 114 (24.8%)
Theoretical education incl. BA level 789 (44.4%) 742 (44.3%) 156 (44.6%) 217 (47.3%)
Master level or more 620 (34.9%) 602 (36.0%) 92 (26.3%) 124 (27.0%)
Maternal smoking during pregnancy * N (%) 168 (9.4%) 155 (9.3%) 39 (11.1%) 60 (13.1%)
Premature, GA < 37 weeks N (%) 56 (3.2%) 59 (3.5%) 15 (4.3%) 14 (3.1%)
Child age at 12 month developmental follow-up,
days
Median 377 (365–447) 378 (365–460) NA NA
(10th– 90th
percentile)
Child sex, boys N (%) 922 (52.2%) 888 (53.1%) 176 (50.3%) 249 (54.3%)
Older biological siblings N (%) 727 (40.9%) 664 (39.7%) 178 (50.9%) 192 (41.8%)
Child exclusively breastfed at three month follow-
up¤
N (%) 1032 (58.0%) 955 (57.5%) 183 (52.3%) 219 (47.7%)
Multiple birth N (%) 53 (3.0%) 62 (3.7%) 15 (4.3%) 22 (4.8%)
# Unknown n = 13,
* Unknown n = 2,
¤ Unknown = 41.
SD: Standard deviation, 95% CI: 95% conﬁdence interval, BA: Bachelor, NA: not applicable.
doi:10.1371/journal.pone.0154541.t001
Table 2. Primary and secondary outcomes; ASQ score at 12 months.
N = 4262 Mean ASQ score (SD) Effect of BCG¤ (95% CI) Cohen’s d (95% CI) P-value
n BCG Controls
Primary outcome
ASQ sum score 3453 178.2 (52.4) 179.9 (53.6) -0.7* (-3.7 to 2.4) -0.015 (-0.082 to 0.052) 0.67
Sensitivity analysis
ASQ sum score 3453 178.2 (52.4) 179.9 (53.6) -0.5& (-3.4 to 2.5) -0.011 (-0.078 to 0.057) 0.76
Secondary outcomes
Communication score 3453 29.2 (13.1) 29.7 (13.3) -0.3* (-1.0 to 0.5) -0.023 (-0.089 to 0.044) 0.51
Fine motor score 3453 37.8 (19.2) 38.0 (19.2) 0.1* (-1.1 to 1.3) 0.0062 (-0.061 to 0.073) 0.86#
Gross motor score 3453 38.2 (12.6) 38.7 (12.7) -0.3* (-1.1 to 0.4) -0.030 (-0.096 to 0.037) 0.38
Problem solving score 3453 36.6 (13.6) 36.7 (14.1) 0.1* (-0.8 to 1.0) 0.008 (-0.058 to 0.075) 0.81
Personal and social development score 3453 36.2 (13.3) 36.7 (13.3) -0.3* (-1.1 to 0.5) -0.022 (-0.089 to 0.044) 0.51
* Adjusted for prematurity and age at follow-up,
& Adjusted for prematurity, age at follow-up, child sex, study site, gestational age in days, maternal year of birth, maternal education, multiple birth,
maternal smoking during pregnancy, older siblings,
¤ Multiple regression beta-coefﬁcients,
# Distribution not normal.
Sensitivity analyses; Mann-Whitney U = 0.88, ASQ: Ages and Stages Questionnaire, 95% CI: 95% Conﬁdence interval, BCG: Bacillus Calmette-Guérin
vaccine, SD: Standard deviation.
doi:10.1371/journal.pone.0154541.t002
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development, we used a well-known and extensively used questionnaire, the ASQ, which is
completed by parents and has been shown to have high validity, sensitivity and specificity as a
tool for detecting developmental delay[21]. We succeeded in obtaining a distribution of ASQ-
scores with only slight truncation as less than one percent scored the maximum score for the
primary outcome and thus obtained the highest possible power to detect a difference in mean
score for responders. Also, studying possible non-specific effects using a randomised design
yields a low risk of bias. Our study has some limitations that could bias the results towards the
null; we had 14.1% non-responders for the primary outcome. Among non-responders, there
Table 3. Subgroup analysis; Total ASQ-score of premature children (gestational age < 37 weeks) at follow-up.
N = 144 Mean ASQ score (SD) Effect of BCG* (95% CI) Cohen’s d (95% CI) P-value
Follow-up n BCG Controls
6 months
Premature children 98 144.8 (48.7) 140.5 (44.1) -3.1 (-19.3 to 13.0) -0.082 (-0.50 to 0.34) 0.70
12 months
Premature children 115 141.8 (53.0) 153.5 (53.5) -11.5 (-28.7 to 5.7) -0.26 (-0.64 to 0.13) 0.19¤
Term children 3338 179.3 (51.9) 180.8 (53.3) -0.2 (-3.2 to 2.8) -0.0044 (-0.072 to 0.064) 0.90¤
22 months
Premature children 122 213.9 (37.4) 224.7 (30.0) -7.8 (-20.6 to 5.0) -0.23 (-0.62 to 0.15) 0.23
* Multiple regression beta-coefﬁcient adjusted for age at follow-up and gestational age in weeks.
¤ P-value for interaction = 0.20,
ASQ: Ages and Stages Questionnaire, 95% CI: 95% Conﬁdence interval, BCG: Bacillus Calmette-Guérin vaccine, SD: Standard deviation.
doi:10.1371/journal.pone.0154541.t003
Table 4. Per protocol analyses of primary and secondary outcomes and in a sub-group of premature
children.
N = 4262
Analysis n Effect of BCG* (95% CI) P-value
Primary
ASQ sum score 3423 -0.6 (-3.6 to 2.5) 0.70
Secondary
Communication score 3650 -0.4 (-1.1 to 0.4) 0.34
Fine motor score 3644 0.1 (-1.1 to 1.2) 0.88
Gross motor score 3576 -0.4 (-1.2 to 0.4) 0.32
Problem solving score 3452 0.3 (-0.6 to 1.1) 0.56
Personal and social development 3579 -0.4 (-1.2 to 0.4) 0.37
Sub-groups:
6 months
Premature children 98 -0.6 (-16.9 to 15.6) 0.94
12 months
Premature children 114 -11.9 (-28.0 to 4.3) 0.15
Term children 3309 -0.06 (-3.1 to 3.0) 0.97
22 months
Premature children 121 -7.9 (-20.8 to 4.9) 0.22
* Multiple regression beta-coefﬁcient adjusted for age at follow-up and gestational age in weeks.
¤ P-value for interaction = 0.20,
ASQ: Ages and Stages Questionnaire, 95% CI: 95% Conﬁdence interval, BCG: Bacillus Calmette-Guérin
doi:10.1371/journal.pone.0154541.t004
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were more children allocated to the control group, there was a lower level of maternal educa-
tion, and more families with older siblings. We suspected that non-responders did not return
the questionnaires because of one or more of these factors or due to a lower commitment to
the study if the child was in the control group[22], i.e. not due to reasons connected with the
outcome, but this cannot be ascertained. We believe that the risk of differential drop-out is low
since the sensitivity analysis including variables we expected could be associated with drop-out
did not change the primary outcome estimate significantly even though the sensitivity analysis
cannot control for drop-out associated with the outcome. Another important limitation is
the risk of performance bias. Because the parents were not blind to allocation they could
underreport adverse events, but we find it implausible that parents would report their child’s
Fig 2. Box-plots of ASQ sub-domain and total scores at 6, 12, 22 months for premature children. ASQ: Ages and stages questionnaire. Coms:
Communication score. Fms: Fine motor score. Gms: Gross motor score. Pss: Problem solving score. Psds: Personal and social development score. BCG:
Bacillus Calmette-Guèrin vaccine.
doi:10.1371/journal.pone.0154541.g002
Table 5. Sensitivity analyses of ASQ score at 12 months and in the premature subgroup at 6, 12 and 22months.
Mean ASQ score (SD) Mean difference*,BCG vs. control (95% CI) Cohen’s d (95% CI) P-value
Sensitivity analysis of: n BCG Controls
Entire study population
At 12 months 3453 178.2 (52.4) 179.9 (53.2) -0.5 (-3.4 to 2.5) -0.011 (-0.078 to 0.057) 0.76
Premature children
At 6 months 98 144.8 (48.7) 139.0 (45.0) -1.9 (-19.8 to 16.1) -0.051 (-0.55 to 0.45) 0.84
At 12 months 115 141.8 (53.0) 153.5 (53.5) -11.7 (-28.8 to 5.4) -0.30 (-0.74 to 0.14) 0.18
At 22 months 122 213.9 (37.4) 224.7 (30.0) -4.6 (-18.5 to 9.4) -0.14 (-0.58 to 0.29) 0.52
* Regression beta-values adjusted for age at follow-up, child sex, study site, gestational age in days, maternal year of birth, maternal education, multiple
birth, maternal smoking during pregnancy, older siblings.
doi:10.1371/journal.pone.0154541.t005
BCG and Child Psychomotor Development
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development differently based on the allocation in our study, since the parental information
sheet (S2 Text) focused on infectious and atopic diseases, i.e. the primary outcomes of The
Danish Calmette Study. We only recruited approximately 60% of the intended premature chil-
dren due to study logistics and increased parental concern regarding participation in research
in this group. Finally, it is well-described that the immune response to mycobacterial antigens
differs markedly between different strains of BCG[23] and since the effect of BCG on child
development is mediated by the immunological response to the vaccine, the findings of this
study may not extend to other strains.
Studying potentially negative effects in a trial is only ethically permissible if the expected
benefits outweigh the possible side effects. With an expected benefit of a 20% reduction in hos-
pitalisation, we argue that the equipoise required for conducting the trial ethically[24] was
present, especially since the existing evidence indicates that premature children benefit the
most from the non-specific effects of BCG on mortality[3]. To our knowledge, this is the first
study to assess non-specific effects of BCG on psychomotor development. BCG is considered a
safe vaccine and the side effects specific to BCG are well described[25–27]. Serious side effects,
such as disseminated BCG infection or BCG osteitis, are rare[14] but as knowledge on the
immune response generated by BCG as well as on the complex interplay between the immune
system and neuro-development increases[28] so does the range of plausible non-specific
effects, both beneficial and negative. It has been shown that sensitisation with even a small sys-
temic infectious load can lead to increase susceptibility to brain damage following a hypoxic-
ischaemic insult[29] and BCG indeed results in an inflammatory reaction at the injection site
which usually lasts for 2–4 months[25,27,30], as a potential source of systemic infection. Two
recent reviews concluded that there is a possible link between chronic, low-grade inflammation
in early life and the risk of developing an array of neuro-psychiatric disorders in adolescence or
adulthood[15,17] and the effect of BCG vaccinating adult patients with early multiple sclerosis
only became apparent after 18 months and the effect seemed to increase with time[31]. Thus,
our reassuring result at one year of life does not exclude later effects—adverse or beneficial.
In order to corroborate or refute the negative effect estimate we found in premature chil-
dren, we suggest that neurodevelopmental outcomes are assessed, preferably using ASQ, as
part of ongoing and future BCG trials for premature children, even if data would perhaps need
to be pooled across studies in order to achieve sufficient power. Perhaps especially so in popu-
lations with low prevalence of tuberculosis and a low burden of neonatal infections, i.e. a set-
ting in which the non-specific beneficial effect of BCG on mortality is likely to play a minor
role and where prevention of tuberculosis is not a priority at the community level. Conversely,
in low-resource settings where a beneficial effect of BCG on all-cause mortality has been dem-
onstrated, the findings from this study should not deter BCG vaccination of premature chil-
dren, who seem to benefit the most[3].
Conclusion
A clinically significant negative non-specific effect of BCG vaccination at birth on psychomotor
development at 12 months of age was excluded in children born to term. No clear conclusion
on effect in premature children (GA< 37 weeks) was possible in the present study.
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